Natera, Inc. (NTRA)
404.79
+10.04
(+2.54%)
USD |
NASDAQ |
Oct 15, 16:00
405.00
+0.21
(+0.05%)
After-Hours: 06:04
Natera Research and Development Expense (Quarterly) : 228.07M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 228.07M |
| March 31, 2026 | 210.70M |
| December 31, 2025 | 175.19M |
| September 30, 2025 | 173.41M |
| June 30, 2025 | 146.43M |
| March 31, 2025 | 129.08M |
| December 31, 2024 | 129.46M |
| September 30, 2024 | 96.93M |
| June 30, 2024 | 89.11M |
| March 31, 2024 | 88.64M |
| December 31, 2023 | 82.96M |
| September 30, 2023 | 77.24M |
| June 30, 2023 | 78.17M |
| March 31, 2023 | 82.31M |
| December 31, 2022 | 87.91M |
| September 30, 2022 | 65.51M |
| June 30, 2022 | 82.58M |
| March 31, 2022 | 80.41M |
| December 31, 2021 | 71.81M |
| September 30, 2021 | 98.46M |
| June 30, 2021 | 53.75M |
| March 31, 2021 | 40.19M |
| December 31, 2020 | 32.38M |
| September 30, 2020 | 26.42M |
| June 30, 2020 | 23.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 18.22M |
| December 31, 2019 | 15.00M |
| September 30, 2019 | 12.80M |
| June 30, 2019 | 12.12M |
| March 31, 2019 | 11.44M |
| December 31, 2018 | 12.77M |
| September 30, 2018 | 12.39M |
| June 30, 2018 | 11.85M |
| March 31, 2018 | 12.80M |
| December 31, 2017 | 13.02M |
| September 30, 2017 | 12.61M |
| June 30, 2017 | 11.79M |
| March 31, 2017 | 12.07M |
| December 31, 2016 | 11.46M |
| September 30, 2016 | 11.34M |
| June 30, 2016 | 10.30M |
| March 31, 2016 | 8.759M |
| December 31, 2015 | 8.004M |
| September 30, 2015 | 7.336M |
| June 30, 2015 | 6.741M |
| March 31, 2015 | 5.63M |
| September 30, 2014 | 4.372M |
| June 30, 2014 | 4.122M |
| March 31, 2014 | 4.298M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Guardant Health, Inc. | 96.53M |
| Myriad Genetics, Inc. | 25.00M |
| CareDx, Inc. | 22.38M |
| Caris Life Sciences, Inc. | 32.36M |
| BioRestorative Therapies, Inc. | 1.926M |